ZTSZoetis

$74.80-49% 1Y

$74.80

$69.1152 weeks$145.76

Is the price fair?

Fair

Neither cheap nor expensive: nothing decisive, though cheap against its own history.

1 good, 1 neutral, 1 without data

What the price assumes~+1% a yearderived · Jun 30, 2026

Priced for ~1% a year FCF growth. Roughly in line with its three-year revenue growth of 5% a year.

Vs its own P/E rangecheapest in 41 quartersderived

Cheap vs its own history: P/E 12.3 vs a 34.8 median over 41 quarters (−65% vs median).

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)better than 80% of the market

FCF yieldbetter than 70% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

Zoetis trades at 12.3× earnings against 19.7× for the median Drug Manufacturers - Specialty & Generic name, cheaper than its own group.

12.3

Trailing P/E · Drug Manufacturers - Specialty & Generic median 19.7 · cheaper than the typical name in its group

Price / sales: 3.47
Price / sales · today's price, trailing year to Jun 30, 2026
Free cash flow yield: 7.0%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.9%
Growth the price implies: +1.1%
Growth the price implies · The price pays for +1.1% free cash flow growth a year for a decade; the business has delivered +22% a year over the last three.